Javascript must be enabled to continue!
Trabeculectomy with mitomycin C alone or with mitomycin C plus intracameral bevacizumab—A comparative study
View through CrossRef
PurposeTo compare the long‐term outcomes of trabeculectomy using mitomycin C (MMC) alone versus MMC plus intracameral bevacizumab.MethodsRetrospective, comparative study (#ISRCTN93098069). Patients’ charts from two centers were reviewed for data between October 2015 and March 2019. Minimum follow‐up of 12 months was required. The main efficacy outcome was intraocular pressure (IOP) lowering at 12 and 24 months, with surgical success defined as IOP ≤18 mmHg and >5 mmHg with at least 30% reduction from baseline. Absolute success was achieved if no IOP‐lowering medication was needed and a qualified success considered otherwise. Safety outcomes were also analyzed.ResultsA total of 111eyes underwent trabeculectomy with MMC, 52 of them combined with intracameral bevacizumab. 78% were followed for at least two years. Baseline IOP was 24.5 ± 8.9 mmHg and 23.8 ± 8.3 mmHg for the MMC and the MMC+bevacizumab groups, respectively (p = 0.97). During the early post‐operative period (at 3 months), mean IOP was lower in the MMC+bevacizumab group (9.3 ± 2.3 mmHg versus 11.1 ± 5.5 mmHg, p = 0.03). At 24‐month visit, IOP was significantly reduced (MMC group: 10.6 ± 3.4 mmHg; MMC+bevacizumab group: 10.9 ± 4.1 mmHg, p < 0.01) with no difference between groups (p = 0.61). Absolute success was higher in the MMC+bevacizumab group at 12 months (86% versus 75%, p = 0.16) and at 24 months (83% versus 67%, p = 0.14), with the need for IOP‐lowering re‐interventions (needlings) being lower in this group (2% versus 17%, p = 0.01). Almost all patients (98%) of the MMC+bevacizumab group were drop‐free at 12 months and nearly half (44%) had an IOP in the single‐digit range (≤ 9 mmHg) at 24 months. Complication rates were low and similar between groups, with no systemic adverse events.ConclusionsAdding perioperative intracameral bevacizumab to the standard of care use of MMC in trabeculectomy seems to allow for sustained low IOP outcomes. Furthermore, it seems to decrease the need for additional interventions during the early post‐operative period.
Title: Trabeculectomy with mitomycin C alone or with mitomycin C plus intracameral bevacizumab—A comparative study
Description:
PurposeTo compare the long‐term outcomes of trabeculectomy using mitomycin C (MMC) alone versus MMC plus intracameral bevacizumab.
MethodsRetrospective, comparative study (#ISRCTN93098069).
Patients’ charts from two centers were reviewed for data between October 2015 and March 2019.
Minimum follow‐up of 12 months was required.
The main efficacy outcome was intraocular pressure (IOP) lowering at 12 and 24 months, with surgical success defined as IOP ≤18 mmHg and >5 mmHg with at least 30% reduction from baseline.
Absolute success was achieved if no IOP‐lowering medication was needed and a qualified success considered otherwise.
Safety outcomes were also analyzed.
ResultsA total of 111eyes underwent trabeculectomy with MMC, 52 of them combined with intracameral bevacizumab.
78% were followed for at least two years.
Baseline IOP was 24.
5 ± 8.
9 mmHg and 23.
8 ± 8.
3 mmHg for the MMC and the MMC+bevacizumab groups, respectively (p = 0.
97).
During the early post‐operative period (at 3 months), mean IOP was lower in the MMC+bevacizumab group (9.
3 ± 2.
3 mmHg versus 11.
1 ± 5.
5 mmHg, p = 0.
03).
At 24‐month visit, IOP was significantly reduced (MMC group: 10.
6 ± 3.
4 mmHg; MMC+bevacizumab group: 10.
9 ± 4.
1 mmHg, p < 0.
01) with no difference between groups (p = 0.
61).
Absolute success was higher in the MMC+bevacizumab group at 12 months (86% versus 75%, p = 0.
16) and at 24 months (83% versus 67%, p = 0.
14), with the need for IOP‐lowering re‐interventions (needlings) being lower in this group (2% versus 17%, p = 0.
01).
Almost all patients (98%) of the MMC+bevacizumab group were drop‐free at 12 months and nearly half (44%) had an IOP in the single‐digit range (≤ 9 mmHg) at 24 months.
Complication rates were low and similar between groups, with no systemic adverse events.
ConclusionsAdding perioperative intracameral bevacizumab to the standard of care use of MMC in trabeculectomy seems to allow for sustained low IOP outcomes.
Furthermore, it seems to decrease the need for additional interventions during the early post‐operative period.
Related Results
Acceptance & Barriers to Trabeculectomy among patients with Glaucoma: A Cross-sectional study
Acceptance & Barriers to Trabeculectomy among patients with Glaucoma: A Cross-sectional study
Objective: This study aimed to assess the level of acceptance about trabeculectomy and to determine patient-perceived barriers to trabeculectomy among glaucoma patients attending ...
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract
Bevacizumab-containing protocols are all based upon the concomitant administration of the drugs given in a row. Bevacizumab is expected to induce a transien...
Primerjalna književnost na prelomu tisočletja
Primerjalna književnost na prelomu tisočletja
In a comprehensive and at times critical manner, this volume seeks to shed light on the development of events in Western (i.e., European and North American) comparative literature ...
Comparison of Trabeculectomy with combined PhacoTrabeculectomy in the treatment of Angle closure Glaucoma
Comparison of Trabeculectomy with combined PhacoTrabeculectomy in the treatment of Angle closure Glaucoma
Background: Trabeculectomy has always been a mainstream treatment in reducing intraocular pressure (IOP) for primary angle closure glaucoma
(PACG); combined Trabeculectomy and Phac...
A Comparative Study on Intraoperative Local Mitomycine_ c Application in Primary Endoscopic Dacrocystorhinostomy (dcr) with Conventional Primary Endoscpic (dcr).
A Comparative Study on Intraoperative Local Mitomycine_ c Application in Primary Endoscopic Dacrocystorhinostomy (dcr) with Conventional Primary Endoscpic (dcr).
Epiphora is an overflow of tears onto the face due to imperfect drainage of the tear conducting passages or excess lacrimal production. Dacrocystorhinostomy ( DCR) is recognized a...
Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma
Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma
<i>Purpose:</i> To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). <i>Me...
EFFICACY OF INTRACAMERAL MOXIFLOXACIN VERSUS TOPICAL MOXIFLOXACIN IN PREVENTING ACUTE ENDOPHTHALMITIS AFTER CATARACT SURGERY BY PHACOEMULSIFICATION
EFFICACY OF INTRACAMERAL MOXIFLOXACIN VERSUS TOPICAL MOXIFLOXACIN IN PREVENTING ACUTE ENDOPHTHALMITIS AFTER CATARACT SURGERY BY PHACOEMULSIFICATION
Background: Endophthalmitis is an acute infection of anterior and posterior segment of the eye involving aqueous humour and vitreous cavity along with the other structures. It is c...
Role of intravitreal/intracameral antibiotics to prevent traumatic endophthalmitis – Meta-analysis
Role of intravitreal/intracameral antibiotics to prevent traumatic endophthalmitis – Meta-analysis
Traumatic endophthalmitis is a devastating condition that can occur following an open globe injury and result in loss of vision. The use of prophylactic antibiotics is empirical as...

